Aptar Announces the Realignment of Two of its Business Reporting Segments
AptarGroup, Inc. (NYSE: ATR) announced a realignment of its business reporting segments, effective January 1, 2023. The new segments, Aptar Closures and Aptar Beauty, aim to streamline operations and enhance customer focus. The Aptar Closures segment will consolidate closures expertise to broaden market reach, while Aptar Beauty will focus on complex dispensing solutions for various markets. The company will continue to report on three segments, including Aptar Pharma, and will disclose recast historical financials prior to its first quarter results.
- Realignment of reporting segments aims to improve operational efficiencies.
- Consolidation of closures expertise could enhance market reach and customer service.
- Focus on Aptar Beauty may strengthen competitive position in multiple markets.
- None.
The Company’s Pharma Segment Remains Unchanged
Aptar Closures will focus specifically on leveraging the closures platform with an aim of broadening the markets that Aptar serves with these technologies. Combining Aptar’s closures activities into one segment will allow the Company to better serve customers by concentrating its closures product design, marketing and manufacturing expertise. Additionally, the emphasis on closures within one segment will help to streamline operations and better leverage these capabilities.
The realignment will also focus and simplify Aptar Beauty and strengthen the Company’s competitive position. Aptar Beauty will develop and provide complex spray and dispensing solutions for the fragrance, cosmetics, skincare and personal care markets. The segment will also supply home care, food and beverage customers that use spray or pump dispensing technologies.
“We are taking a strategic step that will strengthen our competitive position by simplifying and focusing our organization,” said
Aptar will continue to have three reporting segments: Aptar Pharma, Aptar Beauty and Aptar Closures. Aptar will disclose the recast historical financials of the new segments before its first quarter 2023 results.
About Aptar
Aptar is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions and services. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home care, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in
This press release contains forward-looking statements, including the potential benefits of the realignment of our business reporting segments. Future or conditional verbs such as “will” and other similar expressions are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment. For additional information on these and other risks and uncertainties, please see our filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20221212005730/en/
Investor Relations Contact:
mary.skafidas@aptar.com
+1 347-351-6407
Media Contact:
katie.reardon@aptar.com
+1 815-479-5671
Source:
FAQ
What is AptarGroup's new segment structure effective January 1, 2023?
How will the realignment affect Aptar's operations?
What does the Aptar Closures segment focus on?
Will Aptar continue to report on Aptar Pharma?